Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / B••••••••• R••••••• F•••

B••••••••• R••••••• F•••, West Coast Clinical Trials, Receives Equity Investment from H••••••••• P••••••• to Support Expansion

Platform acquisitionannouncedannounced Jan 10, 2012Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
healthcare / clinic, pharma
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • M••• H•••••••••, Managing Director of H•••••••••, said, “Thanks to Founder and CEO Dr. Kenneth Kim and the management team, WCCT Global is well positioned for continued growth.
  • Cypress, California and San Francisco – January 10, 2012 – West Coast Clinical Trials, LLC (WCCT), a contract research organization (CRO) supporting early phase biopharmaceutical and device development, today announced it has received a substantial equity investment from H••••••••• P•••••••, a $1 bi
Side not stated
Evidence
B••••••••• R••••••• F•••, West Coast Clinical Trials, Receives Equity Investment from H••••••••• P••••••• to Support Expansion
B••••••••• R••••••• F•••, West Coast Clinical Trials, Receives Equity Investment from H••• | Private Equity Intelligence | DFX